<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03380611</url>
  </required_header>
  <id_info>
    <org_study_id>METC 17-3-022</org_study_id>
    <nct_id>NCT03380611</nct_id>
  </id_info>
  <brief_title>Algae and Cholesterol Absorption</brief_title>
  <official_title>Effects of Wakame and Spirulina Consumption on Intestinal Cholesterol Absorption in Non- Hypercholesterolemic Men and Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to investigate the effects of wakame and spirulina&#xD;
      consumption on intestinal cholesterol absorption.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:&#xD;
&#xD;
      Secondary objectives are to investigate the effects of wakame and spirulina consumption on&#xD;
      fasting markers for lipid metabolism, glucose metabolism and blood pressure.&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      This study is a double-blinded, randomized, placebo-controlled, crossover intervention trial&#xD;
      consisting of three intervention periods of 17 days each, separated by a minimum washout&#xD;
      period of 14 days.&#xD;
&#xD;
      Study population:&#xD;
&#xD;
      The study population will consist of 37 healthy, non-hypercholesterolemic men and women aged&#xD;
      between 18 and 70 years.&#xD;
&#xD;
      Intervention:&#xD;
&#xD;
      All subjects will receive wakame, spirulina and placebo capsules in randomized order.&#xD;
      Subjects will be asked to consume 12 capsules per day for 17 days, which is equal to 4.8&#xD;
      grams of wakame or spirulina a day.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 24, 2017</start_date>
  <completion_date type="Actual">August 16, 2018</completion_date>
  <primary_completion_date type="Actual">August 16, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Markers for intestinal cholesterol absorption</measure>
    <time_frame>Difference in outcomes between interventions and control at 17 days</time_frame>
    <description>Serum cholesterol-standardized campesterol concentrations will be measured as a marker for intestinal cholesterol absorption</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lipids</measure>
    <time_frame>Difference in outcomes between interventions and control at 17 days</time_frame>
    <description>Several markers for fasting lipid metabolism, including total cholesterol, LDL cholesterol and HDL cholesterol, will be measured in blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers for cholesterol synthesis</measure>
    <time_frame>Difference in outcomes between interventions and control at 17 days</time_frame>
    <description>Serum cholesterol-standardized lathosterol and desmosterol concentrations will be measured as a markers for cholesterol synthesis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose concentrations</measure>
    <time_frame>Difference in outcomes between interventions and control at 17 days</time_frame>
    <description>Fasting plasma glucose concentrations will be determined</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Difference in outcomes between interventions and control at 17 days</time_frame>
    <description>Systolic and diastolic blood pressure will be determined</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Intestinal Cholesterol Absorption</condition>
  <arm_group>
    <arm_group_label>Wakame</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive capsules containing wakame</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Spirulina</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive capsules containing spirulina</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive capsules containing microcrystalline cellulose</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Wakame</intervention_name>
    <description>Consumption of 4.8 grams wakame per day for 17 days</description>
    <arm_group_label>Wakame</arm_group_label>
    <other_name>Undaria pinnatifida</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Spirulina</intervention_name>
    <description>Consumption of 4.8 grams spirulina per day for 17 days</description>
    <arm_group_label>Spirulina</arm_group_label>
    <other_name>Arthrospira</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Consumption of microcrystalline cellulose for 17 days</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged between 18 and 70 years;&#xD;
&#xD;
          -  BMI between 18 and 30 kg/m2;&#xD;
&#xD;
          -  Non-smoking;&#xD;
&#xD;
          -  No elevated serum triacylglycerol concentrations (&lt; 4.5 mmol/L);&#xD;
&#xD;
          -  Willing to comply to the study protocol during the study;&#xD;
&#xD;
          -  Agreeing to be informed about medically relevant personal test-results.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not willing to abstain from any algae and/or seaweed consumption or algae/seaweed&#xD;
             containing products two weeks before the start and during the trial;&#xD;
&#xD;
          -  Use of plant-sterol/stanol-enriched foods (e.g. Becel Proactive) or supplements in the&#xD;
             four weeks prior to the screening and/or during the study;&#xD;
&#xD;
          -  Use of cholesterol or lipid-lowering medications (e.g. statins, bile-acid&#xD;
             sequestrates, cholesterol absorption inhibitors);&#xD;
&#xD;
          -  Use of any kind of medication or a medically prescribed diet, which can interfere with&#xD;
             the study;&#xD;
&#xD;
          -  Use of oral antibiotics in 40 days or less prior to the start of the study;&#xD;
&#xD;
          -  Use of food supplements that might interfere with study measurements (judged by the&#xD;
             principal investigator) in four weeks or less prior to the start of the study;&#xD;
&#xD;
          -  Indications of treatment according to the Standard for Cardiovascular Risk Management&#xD;
             from the Dutch General Practitioners community;&#xD;
&#xD;
          -  Any medical condition that might interfere with study (measurements), judged by the&#xD;
             principal investigator, including cardiovascular diseases or events (e.g. acute&#xD;
             myocardial infarction or cerebro-vascular accident), diabetes, asthma, COPD,&#xD;
             rheumatoid arthritis, and gastro-intestinal diseases (e.g. inflammatory bowel&#xD;
             disease);&#xD;
&#xD;
          -  Unstable body weight (weight gain or loss &gt; 3 kg in the past 3 months);&#xD;
&#xD;
          -  Females who are pregnant, breast feeding or who may wish to become pregnant during the&#xD;
             study;&#xD;
&#xD;
          -  Consumption of &gt; 14 (males) or &gt; 10 (females) alcoholic consumptions a week;&#xD;
&#xD;
          -  Reported intense sporting activities &gt; 10 hours a week;&#xD;
&#xD;
             ￼• Abuse of drugs;&#xD;
&#xD;
          -  Participation in any other biomedical trial four weeks prior to the screening visit;&#xD;
&#xD;
          -  Having donated &gt;150 ml blood within 1 month prior to the screening visit, planning to&#xD;
             donate blood during the study or within one month after finishing the study;&#xD;
&#xD;
          -  Impossible or difficult to puncture as evidenced during the screening visit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald Mensink, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jogchum Plat, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6229ER</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>December 7, 2017</study_first_submitted>
  <study_first_submitted_qc>December 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 21, 2017</study_first_posted>
  <last_update_submitted>October 18, 2018</last_update_submitted>
  <last_update_submitted_qc>October 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

